{
    "root": "469917c3-716f-4957-8f39-e44993f9561e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enspryng",
    "value": "20250508",
    "ingredients": [
        {
            "name": "SATRALIZUMAB",
            "code": "YB18NF020M"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "ASPARTIC ACID",
            "code": "30KYC7MIAI"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "enspryng indicated treatment neuromyelitis optica spectrum disorder ( nmosd ) adult patients anti-aquaporin-4 ( aqp4 ) antibody positive .",
    "contraindications": "hepatitis b virus , tuberculosis , liver transaminase screening required first dose . ( 2.1 ) prior every , determine active infection . ( 2.2 ) recommended loading enspryng first three administrations 120 mg subcutaneous injection weeks 0 , 2 , 4 , followed maintenance 120 mg every 4 weeks . ( 2.2 ) full prescribing information important preparation instructions . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "enspryng contraindicated patients : known hypersensitivity satralizumab inactive ingredients [ ( 5.4 ) ] active hepatitis b infection [ ( 5.1 ) ] active untreated latent tuberculosis [ ( 5.1 ) ]",
    "indications_original": "ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.",
    "contraindications_original": "Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose. ( 2.1 ) Prior to every use, determine if there is an active infection. ( 2.2 ) The recommended loading dosage of ENSPRYNG for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. ( 2.2 ) See Full Prescribing Information for important preparation and administration instructions. ( 2.3 )",
    "adverseReactions_original": "ENSPRYNG is contraindicated in patients with:\n                  \n                     A known hypersensitivity to satralizumab or any of the inactive ingredients [see Warnings and Precautions (5.4)]\n                     \n                     Active Hepatitis B infection [see Warnings and Precautions (5.1)]\n                     \n                     Active or untreated latent tuberculosis [see Warnings and Precautions (5.1)]"
}